Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Purchases 2,985 Shares

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) CEO Benjamin J. Zeskind bought 2,985 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The stock was purchased at an average price of $3.38 per share, with a total value of $10,089.30. Following the transaction, the chief executive officer directly owned 2,305,837 shares in the company, valued at $7,793,729.06. The trade was a 0.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Immuneering Stock Down 4.9%

Shares of Immuneering stock traded down $0.18 on Thursday, hitting $3.42. The stock had a trading volume of 624,406 shares, compared to its average volume of 2,537,607. Immuneering Corporation has a one year low of $1.00 and a one year high of $3.87. The stock's 50-day simple moving average is $1.92 and its two-hundred day simple moving average is $1.81. The stock has a market cap of $122.91 million, a price-to-earnings ratio of -1.74 and a beta of 0.38.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). As a group, equities analysts predict that Immuneering Corporation will post -1.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Oppenheimer decreased their price target on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Chardan Capital reiterated a "buy" rating and issued a $13.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Needham & Company LLC reissued a "buy" rating and issued a $9.00 price target on shares of Immuneering in a research note on Wednesday, June 18th. Finally, Mizuho raised their price objective on Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Wednesday, June 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $13.25.

Institutional Trading of Immuneering

Several large investors have recently modified their holdings of the business. Tang Capital Management LLC bought a new position in Immuneering during the 4th quarter valued at approximately $27,000. Jane Street Group LLC bought a new stake in shares of Immuneering in the 1st quarter worth approximately $32,000. Marshall Wace LLP purchased a new position in shares of Immuneering during the fourth quarter valued at approximately $47,000. First Manhattan CO. LLC. bought a new position in shares of Immuneering during the fourth quarter valued at approximately $71,000. Finally, XTX Topco Ltd lifted its stake in Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after acquiring an additional 20,871 shares during the period. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.